iproniazid has been researched along with Lupus Erythematosus, Systemic in 1 studies
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The syndrome resembling systemic lupus erythematosus (SLE) associated with long-term treatment with hydralazine and isoniazid seems to be due to the drugs themselves rather than their metabolites." | 1.27 | Drugs that induce systemic lupus erythematosus inhibit complement component C4. ( Gill, EW; Sim, E; Sim, RB, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sim, E | 1 |
| Gill, EW | 1 |
| Sim, RB | 1 |
1 other study available for iproniazid and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Drugs that induce systemic lupus erythematosus inhibit complement component C4.
Topics: Acetylation; Complement C4; Complement Pathway, Classical; Humans; Hydralazine; Iproniazid; Isoniazi | 1984 |